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allele in the mother. This association requires independent
validation and further investigation of the mechanism by which
the mare’s genetic background contributes to pregnancy out-
come.
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Equine viral arteritis (EVA) is a respiratory and reproductive dis-
ease of widespread occurrence among equid populations. EAV can
cause long-term persistent infection in 10-70% of the infected
stallions (carrier state), and the establishment and maintenance
of EAV carrier state is testosterone-dependent. Carrier stallions
constitute the natural reservoir of EAV and they continue to shed
virus in semen for a long period of time ranging from weeks to
life-long., EVA has a signiﬁcant economic impact on the equine
breeding industry due to the restriction of international move-
ment of horses and the use of carrier stallions for natural and
artiﬁcial breeding. Several therapeutic approaches to clear the
carrier state (gonadotropin releasing hormone [GnRH] antago-
nists, anti-GnRH vaccination, antiviral compounds) or eliminate
semen infectivity, (single-layer centrifugation) have been evalu-
ated. However, none of them guaranteed clearance of persistent
infection or elimination of virus infectivity from semen. Conse-
quently, there are currently still no means available to fully
eliminate the carrier state other than castration, which implicates
the loss of the commercial value of the stallion. In the 1990’s,
heavy chain antibodies (HCAbs) were characterized in members
of the Camelidae family. HCAbs are devoid of both the light chain
and a constant heavy domain (CH1), and contain an antigen-
speciﬁc variable heavy chain domain (VHH). This single VHH
domain is also known as Nanobody (Nb). Several beneﬁcial
properties (size, afﬁnity, stability, target accessibility) in combi-
nation with easy and low production costs has lead to their suc-
cess as potential therapeutic agents for a variety of human and
animal diseases. The objective of this study was to develop EAV-
speciﬁc neutralizing Nbs as a potential therapy to induce viral
clearance in carrier stallions. A single llama was immunized on
days 0,14, 28, and 57with 1.5 ml of the modiﬁed live virus vaccine
strain (ARVAC®) and the Argentina 2010 ﬁeld strain of EAV (107.5
TCID50/ml). Seroconversion was demonstrated following the OIE
(World Organisation for Animal Health)-prescribed virus
neutralization test (VNT; titer 1:6,400). Four days after the ﬁnal
boost, peripheral blood mononuclear cells were isolated from the
buffy coat fraction by gradient centrifugation, lysed, and total RNA
was obtained by phenol/chloroform extraction. The cDNA was
synthesized using oligo(dT) primers, followed by a two-step
nested polymerase chain reaction (nPCR) to amplify the VHH
repertoire. The primers used for the ﬁrst ampliﬁcation reaction(CALL001 and CALL002) speciﬁcally anneal to constant and vari-
able domain sequences conserved among all IgG isotypes. PCR
fragments of 700bp corresponding with HCAb sequences were gel
puriﬁed, and subjected to a second PCR reaction using primers,
amplifying speciﬁcally the VHH repertoire. The ﬁnal PCR products
were cloned into the pMECS vector and transformed TG1 elec-
trocompetent E.coli. A library of 3.3x107 transformants was
generated, with 71% containing the correct insert size as deter-
mined by colony PCR. Panning of the VHH repertoire by phage
display using a panel of recombinant EAV major structural pro-
teins is currently ongoing. In conclusion, a VHH library derived
from llama B cells following immunization with EAV was gener-
ated. This novel strategy could allow the generation of EAV-spe-
ciﬁc neutralizing Nbs as a therapeutic approach to induce
clearance of EAV carrier state in stallions.
013
Construction and manipulation of a full-length
infectious bacterial artiﬁcial chromosome clone of
equine herpesvirus type 3
A.M. Damiani*, M. Akhmedzhanov, N. Osterrieder
Institut für Virologie, Zentrum für Infektionsmedizin - Robert von
Ostertag-Haus, Freie Universit€at Berlin, 14163 Berlin, Germany
Equine herpesvirus type 3 (EHV-3) is the causal agent of equine
coital exanthema, a disease characterized by pox-like lesions on
the penis of stallions and the vulva of mares. Although the com-
plete genomic sequence of EHV-3 has been recently made avail-
able, its genomic content remains poorly characterized and the
molecularmechanisms of disease development not yet elucidated.
In an attempt to facilitate the genetic manipulation of EHV-3, we
describe here the construction of a full-length infectious bacterial
artiﬁcial chromosome (BAC) clone of EHV-3. Mini-F vector se-
quences were inserted into the intergenic region between ORF19
and ORF20 (the UL41 and UL40 homologs, respectively) of EHV-3
strain C175 by homologous recombination in equine dermis cells
(Nbl-6). DNA of the resulting recombinant virus was electro-
porated into E. coli and a full-length EHV-3 BAC clone was recov-
ered. The reconstituted virus obtained after transfection of the
EHV-3 BAC into Nbl-6 cells showed growth properties in vitro that
were indistinguishable from those of the parental virus. To assess
the feasibility of mutagenesis of the cloned EHV-3 genome, a
mutant virus with a deletion of the glycoprotein E gene was
generated using the Red recombination system in E. coli and its in
vitro growth properties evaluated. The cloning of EHV-3 as a BAC
will simplify future studies to identify the roleof its codinggenes in
viral pathogenesis and host immune response.
Figure. Strategy for generation of the EHV-3 BAC plasmid. (A) The structure
of the EHV-3 genome with the UL and US components is shown at the top.
Terminal and internal repeat sequences are indicated (B) Genomic organi-
zation from ORF18 to ORF21 of the UL region of the EHV-3 genome.
Representative positions of the primers used for ampliﬁcation and subse-
quent cloning of homologous arms are shown. (C) The mini-F vector
(enclosing sequences for F-plasmid replication and the cat gene), the
eukaryotic selection marker xgpt and the gfp gene were integrated between
the ORF19 and ORF 20 ORFs in the UL region of the EHV-3 viral genome by
homologous recombination in Nbl-6 cells. A full-length EHV-3 BAC clone
was recovered after electroporation in E. coli.
